JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M702206200 on April 23, 2007

J. Biol. Chem., Vol. 282, Issue 24, 17581-17586, June 15, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/24/17581    most recent
M702206200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, M.
Right arrow Articles by Zhou, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, M.
Right arrow Articles by Zhou, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

PO2-dependent Differential Regulation of Multidrug Resistance 1 Gene Expression by the c-Jun NH2-terminal Kinase Pathway*Formula

Min Liu{ddagger}, Dengwen Li{ddagger}, Ritu Aneja§, Harish C. Joshi§, Songbo Xie{ddagger}, Chao Zhang{ddagger}, and Jun Zhou{ddagger}1

From the {ddagger}Department of Genetics and Cell Biology and Key Laboratory of Bioactive Materials (Ministry of Education), College of Life Sciences, Nankai University, Tianjin 300071, China and the §Department of Cell Biology, Emory University School of Medicine, Atlanta, Georgia 30322

Received for publication, March 14, 2007


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Hypoxia-induced multidrug resistance 1 (MDR1) gene expression is known to be mediated by c-Jun NH2-terminal kinase (JNK) activation. However, the molecular mechanisms underlying this action of JNK remain elusive. On the contrary, there has been increasing evidence for a negative correlation of JNK activity with MDR1 expression under normoxic conditions. Here, we present evidence that the JNK pathway represses MDR1 expression in normoxia and activates MDR1 expression in hypoxia. Our data show that JNK pathway-induced MDR1 repression in normoxia is mediated by increased c-Jun binding to activator protein 1 site, located in the MDR1 promoter, and requires the activity of histone deacetylase 5. In contrast, JNK pathway-induced MDR1 activation in hypoxia is independent of the activator protein 1 site. Rather, this action is dependent on increased hypoxia-inducible factor 1 (HIF1) binding to the hypoxia response element in the MDR1 promoter, which is promoted by the interaction of HIF1{alpha} with c-Jun in the nucleus and requires the activity of the p300/CBP (CREB-binding protein) coactivator.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Tissue hypoxia, a decrease in local oxygen tension (PO2), is a common feature of developing tumors. Tumor cells develop various adaptive programs in response to hypoxia, including up-regulation of specific genes that promote tumor survival and growth (1). The key factor that regulates cellular adaptation to low PO2 is hypoxia-inducible factor 1 (HIF1),2 a heterodimer comprising {alpha}- and beta-subunits (2). Although HIF1{alpha} protein is stable only in hypoxia and rapidly degraded in normoxia, HIF1beta protein level is not altered by PO2. Under hypoxic conditions, HIF1{alpha} translocates to the nucleus and dimerizes with HIF1beta to form HIF1, which then binds to the hypoxia response elements (HREs) of target genes and activates their transcription (2).

Multidrug resistance 1 (MDR1) gene, encoding the transmembrane drug transporter P-glycoprotein, is induced in response to hypoxia (3, 4), which may contribute to the observed chemotherapeutic resistance of cancer cells under hypoxic conditions (5). Hypoxia-induced MDR1 expression is mediated by the binding of HIF1 to the HRE located in the MDR1 promoter (3). In addition, activation of the c-Jun NH2-terminal kinase (JNK), a member of the mitogen-activated protein kinase family, has been implicated in hypoxia-induced MDR1 expression (6–8). However, it remains to be elucidated how JNK activation contributes to MDR1 expression in hypoxia. On the other hand, there is a growing body of evidence supporting a negative correlation of JNK activity with MDR1 expression under normoxic conditions (9–11). It is unclear at present whether the discrepancy between these studies results from the use of different cell lines or the variation in experimental protocols or whether it simply reflects different roles for JNK in regulating MDR1 gene expression under normoxic and hypoxic conditions.

In this study, our data demonstrate for the first time that the JNK pathway plays PO2-dependent different roles in regulating MDR1 expression, i.e. down-regulation of MDR1 expression in normoxia and up-regulation of MDR1 expression in hypoxia. Moreover, our data provide important mechanistic insights into the above mentioned PO2-dependent differential regulation of MDR1 expression by the JNK pathway.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Cells, Plasmids, and Adenoviruses—HOP62 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 2 mML-glutamine at 37 °C in a humidified atmosphere with 5% CO2. For hypoxic exposure, cells were placed in an airtight incubator chamber flushed with 1% O2, 5% CO2, and 94% N2. Plasmids and adenoviruses encoding JNK, c-Jun, and other proteins used in this study were prepared as described previously (11, 12).

Western Blot Analysis, Immunocomplex Kinase Assay, and Relevant Antibodies—Proteins were resolved by polyacrylamide gel electrophoresis (10 µg of total protein was loaded per lane), transferred onto polyvinylidene difluoride membranes, and exposed to primary and secondary antibodies, and specific proteins were then visualized with enhanced chemiluminescence reagent as described (13). JNK activity was measured using the immunocomplex JNK kinase assay kit according to the manufacturer's instructions (Calbiochem). Antibodies against P-glycoprotein (1:500 dilution), JNK (1:2000 dilution), c-Jun (1:1000 dilution), phosphorylated c-Jun (1:1000 dilution), and histone deacetylase 5 (HDAC5) (1:500) were obtained from Calbiochem; HIF1{alpha} antibody (1:500 dilution) was from BD Transduction Laboratories; and beta-actin antibody (1:5000 dilution) was from Sigma-Aldrich. Horseradish peroxidase-conjugated anti-rabbit and anti-mouse secondary antibodies (both at a 1:2500 dilution) were purchased from Pierce Biotechnology.

Quantitative Real Time RT-PCR—Total cellular RNA was prepared using the TRIzol reagent (Invitrogen). Quantitative real time RT-PCR was performed in triplicate as described (14). The Ct values in log linear range representing the detection threshold values were used for quantification by the {Delta}{Delta}Ct method, and glyceraldehyde-3-phosphate dehydrogenase was used as a control to normalize the reading for MDR1 in each sample.

Luciferase Reporter Assay—MDR1 promoter activity was measured by using the dual luciferase reporter assay system following the manufacturer's protocol (Promega), with the MDR1 promoter-driven firefly luciferase reporter plasmid pMDR1-Luc and the thymidine kinase-driven Renilla luciferase reporter plasmid pRL-TK. In the pMDR1-Luc plasmid, the MDR1 promoter (from –189 to +133 relative to the major site of transcriptional initiation) was used to drive the firefly luciferase gene as described (15). To minimize experimental variability caused by differences in cell viability and transfection efficiency, the measured firefly luciferase activity was normalized to the thymidine kinase-driven Renilla luciferase activity.

Transcription Factor Binding Assay—Nuclear extracts, prepared as described (12), were incubated in 96-well plates with immobilized oligonucleotide sequences that contain the activator protein 1 (AP1) site or HRE in the MDR1 promoter. The plates were incubated in succession with c-Jun or HIF1{alpha} antibody, horseradish peroxidase-conjugated secondary antibody, and SigmaFast peroxidase substrate (Sigma-Aldrich). The absorbance at a wavelength of 450 nm was then measured to quantify c-Jun/AP1 site and HIF1/HRE binding activities.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
JNK Represses MDR1 Expression in Normoxia and Activates MDR1 Expression in Hypoxia—By Western blot analysis, we found that adenovirus-mediated overexpression of JNK in HOP62 cells reduced P-glycoprotein level in normoxia but enhanced P-glycoprotein level in hypoxia, and hypoxia alone also induced a modest increase in P-glycoprotein level (Fig. 1, A and B). Quantitative real time RT-PCR revealed a similar PO2-dependent regulatory effect of JNK on MDR1 mRNA expression, i.e. down-regulation of MDR1 expression in normoxia and up-regulation of MDR1 expression in hypoxia (Fig. 1C). Hypoxia alone significantly increased MDR1 mRNA expression (Fig. 1C) despite its modest effect on the P-glycoprotein level. Luciferase reporter assay using the MDR1 promoter further showed that transfection of cells with JNK reduced MDR1 promoter activity in normoxia and enhanced MDR1 promoter activity in hypoxia (Fig. 1D). There was also a dramatic increase in MDR1 promoter activity in response to hypoxia alone (Fig. 1D). Together these data demonstrate that JNK regulates MDR1 gene expression negatively in normoxia and positively in hypoxia, in addition to documenting the previous finding that hypoxia is able to activate MDR1 expression (3, 4, 6).


Figure 1
View larger version (37K):
[in this window]
[in a new window]

  		FIGURE 1.
JNK down-regulates MDR1 expression in normoxia and up-regulates MDR1 expression in hypoxia. The values shown in the graphs represent means ± S.D. of data from three independent experiments. A, Western blot analysis of the expression of P-glycoprotein (Pgp), JNK, and actin in HOP62 cells treated for 24 h with JNK adenovirus (m.o.i. = 10) or control (Con.; beta-galactosidase) adenovirus under normoxic or hypoxic conditions. AD, adenovirus. B, experiments were performed as in A, and the P-glycoprotein level was quantified by densitometric analysis of the Western blot bands. The unit shown in the y axis is relative, with the P-glycoprotein level in cells treated with control adenovirus in normoxia set arbitrarily at 1. C, quantitative real time RT-PCR analysis of MDR1 mRNA expression in HOP62 cells treated with JNK adenovirus (m.o.i. = 10) or control adenovirus for 24 h under normoxic or hypoxic conditions. The unit shown in the y axis is relative, with MDR1 level in cells treated with control adenovirus in normoxia set at 1. D, HOP62 cells were transfected for 24 h in normoxia or hypoxia with the MDR1 promoter-driven firefly luciferase reporter plasmid pMDR1-Luc and the thymidine kinase promoter-driven Renilla luciferase reporter plasmid pRL-TK, together with the JNK-expressing plasmid pCDNA3-JNK or the control plasmid pCDNA3. MDR1 promoter activity was calculated by dividing the measured firefly luciferase activity with the measured Renilla luciferase activity. The unit shown in the y axis is relative, with MDR1 promoter activity in cells transfected with the control plasmid in normoxia set at 1. E, Western blot analysis of the expression of P-glycoprotein, JNK, and actin in HOP62 cells treated for 24 h with specific JNK siRNA or control (luciferase) siRNA under normoxic or hypoxic conditions. F, experiments were performed as in E, and the P-glycoprotein level was quantified by densitometry. The unit shown in the y axis is relative, with P-glycoprotein level in cells treated with the control siRNA in normoxia set at 1.

 
To examine whether endogenous JNK also plays distinct roles in regulating MDR1 expression in normoxia and hypoxia, we antagonized the expression of endogenous JNK using specific small interfering RNA (siRNA) and then examined the P-glycoprotein level. Western blot analysis revealed that knockdown of JNK was able to induce P-glycoprotein expression in normoxia and decrease P-glycoprotein expression in hypoxia (Fig. 1, E and F). Similarly, knockdown of JNK by siRNA could increase MDR1 mRNA expression and promoter activity in normoxia and decrease MDR1 mRNA expression and promoter activity in hypoxia (data not shown). Thus, endogenous JNK also possesses the ability to differentially regulate MDR1 expression under normoxic and hypoxic conditions.

Regulation of MDR1 Expression by JNK Is Dependent on JNK Activity and c-Jun in Both Normoxia and Hypoxia—JNK activation is known to contribute to hypoxia-induced MDR1 expression (6–8). In agreement with these studies, we found a time-dependent increase of JNK activity in response to hypoxia (Fig. 2, A and B). Suppression of JNK activity by a specific inhibitor, SP600125, completely abrogated hypoxia-induced MDR1 expression and promoter activity (Fig. 2C and data not shown). Moreover, SP600125 completely inhibited the ability of JNK to repress MDR1 in normoxia and activated MDR1 in hypoxia (Fig. 2C and data not shown), indicating a critical requirement of JNK activity for its regulation of MDR1 expression under both normoxic and hypoxic conditions.

We next investigated whether JNK exerts its PO2-dependent regulatory effect on MDR1 expression through its substrate, the c-Jun transcription factor. As shown in Fig. 2D, knockdown of c-Jun expression using specific siRNA blocked hypoxia-induced MDR1 promoter activity. In addition, JNK-induced repression of MDR1 in normoxia and activation of MDR1 in hypoxia were both abolished by c-Jun siRNA (Fig. 2D). Transfection of cells with c-Jun also exhibited a PO2-dependent regulatory effect on MDR1 promoter activity (Fig. 2E) similar to that observed for transfection with JNK. Thus, c-Jun acts as a pivotal mediator for JNK to regulate MDR1 expression in both normoxia and hypoxia.

We also checked the effects of other components of the JNK pathway, including the upstream kinase MKK4 and upstream kinase kinase MEKK1 (16), on MDR1 gene expression. As shown in Fig. 2E, both MKK4 and MEKK1 could decrease MDR1 promoter activity in normoxia and increase MDR1 promoter activity in hypoxia. In contrast, MKK3 and MEKK2, two molecules not critically involved in the JNK pathway (16), did not have obvious effects on MDR1 promoter activity (Fig. 2E). We also found that MKK4 and MEKK1, but not MKK3 and MEKK2, were able to decrease MDR1 mRNA expression in normoxia and increase MDR1 mRNA expression in hypoxia (data not shown). These results indicate that the PO2-dependent differential regulation of MDR1 expression represents a specific property of the JNK pathway.

Distinct Roles for the AP1 Site and HRE in the MDR1 Promoter in Mediating PO2-dependent Differential Regulation of MDR1 Expression by the JNK Pathway—The MDR1 promoter is known to harbor multiple binding elements, including a negative binding site for the heterodimeric transcription factor AP1 (notably c-Jun/c-Fos), located from –119 to –113 relative to the major transcription start site, and a functional HRE (3, 17, 18). We investigated whether the regulatory effect of the JNK pathway on MDR1 expression is mediated by the alteration of c-Jun binding to the AP1 site. As shown in Fig. 3A, in normoxia both JNK and c-Jun adenoviruses significantly increased c-Jun binding to the AP1 site, whereas in hypoxia neither of them changed the binding of c-Jun to the AP1 site. To further investigate the role for the AP1 site, we performed luciferase reporter assay using an MDR1 promoter harboring mutations in the AP1 site. We found that JNK/c-Jun-induced reduction of MDR1 promoter activity in normoxia was completely abrogated by AP1 site mutations; however, JNK/c-Jun-induced enhancement of MDR1 promoter activity in hypoxia was not obviously affected (Fig. 3B). These data indicate that JNK pathway-induced MDR1 down-regulation in normoxia is mediated by increased c-Jun binding to the AP1 site, whereas JNK pathway-induced MDR1 up-regulation in hypoxia is independent of the AP1 site.


Figure 2
View larger version (38K):
[in this window]
[in a new window]

  		FIGURE 2.
Regulation of MDR1 expression by JNK is dependent on JNK activity and c-Jun in both normoxia and hypoxia. The values shown in the graphs represent means ± S.D. of data from three independent experiments. A, examination of JNK activity in HOP62 cells in normoxia or exposed to hypoxia for 0.5, 1, or 2 h. The level of phosphorylated c-Jun (p-c-Jun) was determined by immunocomplex kinase assay as a measure of JNK activity. JNK expression was examined by Western blot analysis of JNK immunoprecipitates, and actin expression was examined by Western blot analysis of whole cell lysate. B, experiments were performed as in A, and the level of phosphorylated c-Jun was quantified by densitometry. The values shown in the y axis are relative, with the level of phosphorylated c-Jun under the normoxic condition arbitrarily set at 1. C, HOP62 cells were transfected for 12 h in normoxia or hypoxia with pMDR1-Luc and pRL-TK, together with pCDNA3-JNK or the control plasmid, and then treated for another 12 h with the JNK inhibitor SP600125 (20 µM) or the vehicle, Me2SO. MDR1 promoter activity was calculated by dividing the measured firefly luciferase activity with the measured Renilla luciferase activity. The unit shown in the y axis is relative, with MDR1 promoter activity in cells transfected with the control plasmid in normoxia and treated with the vehicle set at 1. D, HOP62 cells were transfected for 12 h in normoxia or hypoxia with pMDR1-Luc and pRL-TK, together with pCDNA3-JNK or the control plasmid, and then treated for 18 h with specific c-Jun siRNA or control (luciferase) siRNA. MDR1 promoter activity was calculated by dividing the measured firefly luciferase activity with the measured Renilla luciferase activity. The unit shown in the y axis is relative, with MDR1 promoter activity in cells transfected with the control plasmid in normoxia and treated with control siRNA (si) set at 1. E, HOP62 cells were transfected for 24 h in normoxia or hypoxia with pMDR1-Luc and pRL-TK, together with a plasmid expressing the indicated protein or a control plasmid. MDR1 promoter activity was calculated by dividing the measured firefly luciferase activity with the measured Renilla luciferase activity. The unit shown in the y axis is relative, with MDR1 promoter activity in cells transfected with the control plasmid in normoxia set at 1.

 


Figure 3
View larger version (43K):
[in this window]
[in a new window]

  		FIGURE 3.
Roles of c-Jun/AP1 site binding, HIF1/HRE binding, and HIF1{alpha}/c-Jun interaction in mediating the PO2-dependent differential regulation of MDR1 expression by the JNK pathway. The values shown in the graphs represent means ± S.D. of data from three independent experiments. A, HOP62 cells were treated for 24 h with JNK (m.o.i. = 10), c-Jun, or control (beta-galactosidase) adenoviruses under normoxic or hypoxic conditions. Nuclear extracts were then prepared and incubated in 96-well plates with immobilized oligonucleotide sequences that contained the AP1 site (APS). The plates were incubated in succession with the c-Jun antibody, horseradish peroxidase-conjugated secondary antibody, and peroxidase substrate. The absorbance at a wavelength of 450 nm was then measured to quantify the c-Jun/AP1 site binding activity. The unit shown in the y axis is relative, with the binding activity in cells treated with control adenovirus in normoxia set at 1. B, HOP62 cells were transfected for 24 h in normoxia or hypoxia with MutAPS (MDR1 promoter harboring mutations in APS)-driven firefly luciferase reporter plasmid and pRL-TK, together with pCDNA3-JNK, pCDNA3-c-Jun, or the control plasmid pCDNA3. MutAPS activity was calculated by dividing the measured firefly luciferase activity with the measured Renilla luciferase activity. The unit shown in the y axis is relative, with MutAPS activity in cells transfected with the control plasmid in normoxia set at 1. C, HOP62 cells were treated for 24 h with JNK (m.o.i. = 10), c-Jun, or control adenoviruses under normoxic or hypoxic conditions. Nuclear extracts were then prepared and incubated in 96-well plates with immobilized oligonucleotide sequences that contained the HRE. The plates were incubated in succession with the HIF1{alpha} antibody, horseradish peroxidase-conjugated secondary antibody, and peroxidase substrate. The absorbance at a wavelength of 450 nm was then measured to quantify the HIF1/HRE binding activity. The unit shown in the y axis is relative, with the binding activity in cells treated with control adenovirus in normoxia set at 1. D, HOP62 cells were transfected for 24 h in normoxia or hypoxia with MutHRE (MDR1 promoter harboring mutations in HRE)-driven firefly luciferase reporter plasmid and pRL-TK, together with pCDNA3-JNK, pCDNA3-c-Jun, or the control plasmid pCDNA3. MutHRE activity was calculated by dividing the measured firefly luciferase activity with the measured Renilla luciferase activity. The unit shown in the y axis is relative, with MutHRE activity in cells transfected with the control plasmid in normoxia set at 1. E, examination of nuclear HIF1{alpha}/c-Jun interaction in HOP62 cells in hypoxia by immunoprecipitation (IP) of nuclear lysate with a c-Jun antibody followed by Western blot analysis with antibodies against HIF1{alpha}, c-Jun, and actin. A non-specific antibody was used in the immunoprecipitation as a negative control for the c-Jun antibody. F, HOP62 cells were treated for 24 h with JNK (m.o.i. = 10), c-Jun, or control adenoviruses in hypoxia or untreated in normoxia. Nuclear extracts were then prepared, and c-Jun was depleted by a specific antibody or mock-depleted. In a parallel experiment, bacterially purified recombinant c-Jun was added to the nuclear extract depleted of c-Jun. The extracts were then incubated in 96-well plates with immobilized oligonucleotide sequences that contained the HRE. The plates were incubated in succession with the HIF1{alpha} antibody, horseradish peroxidase-conjugated secondary antibody, and peroxidase substrate. The absorbance at a wavelength of 450 nm was then measured to quantify the HIF1/HRE binding activity. The unit shown in the y axis is relative, with the binding activity in normoxic cells with mock-depleted nuclear extract set at 1.

 
We then investigated the effects of JNK/c-Jun overexpression on HIF1 binding to the HRE in the MDR1 promoter. We found that JNK and c-Jun adenoviruses did not alter HIF1/HRE binding in normoxia (Fig. 3C). Hypoxia alone significantly increased HIF1/HRE binding, which was further enhanced by overexpression of JNK or c-Jun (Fig. 3C). Luciferase reporter assay using an MDR1 promoter harboring mutations in the HRE revealed that JNK/c-Jun-induced enhancement of MDR1 promoter activity in hypoxia was entirely blocked by HRE mutations (Fig. 3D). In contrast, JNK/c-Jun-induced reduction of MDR1 promoter activity in normoxia was not affected by HRE mutations (Fig. 3D). These data thus indicate that the JNK pathway-induced MDR1 up-regulation in hypoxia is mediated by increased binding of HIF1 to the HRE in MDR1 promoter, but the JNK pathway-induced MDR1 down-regulation in normoxia is independent of the HRE.

The JNK Pathway-induced Increase of HIF1 Binding to the HRE Is Mediated by the Interaction of HIF1{alpha} with c-Jun in the Nucleus—One possibility for the JNK pathway-induced increase of HIF1/HRE binding in hypoxia is that the JNK pathway may increase the HIF1{alpha} protein level. It is also possible that the JNK pathway increases HIF1/HRE binding through a direct or indirect association between nuclear c-Jun and HIF1{alpha}. Western blot analysis of the HIF1{alpha} protein level revealed that JNK/c-Jun overexpression did not affect HIF1{alpha} level in hypoxia (data not shown), thus ruling out the first possibility. We also tested the potential interaction between nuclear c-Jun and HIF1{alpha} in hypoxia. Immunoprecipitation of the nuclear lysate with a c-Jun antibody showed a clear association of endogenous HIF1{alpha} and c-Jun in the nucleus (Fig. 3E). To investigate whether the JNK pathway-induced increase of HIF1/HRE binding in hypoxia is mediated by HIF1{alpha}/c-Jun interaction, we depleted c-Jun from the nuclear lysate using a c-Jun antibody and then examined HIF1/HRE binding. As shown in Fig. 3F, c-Jun depletion not only largely abolished hypoxia-induced HIF1/HRE binding, but it also abolished the ability of JNK and c-Jun to increase HIF1/HRE binding. Furthermore, add-back of purified c-Jun significantly restored HIF1/HRE binding. These results thus indicate that in hypoxia, nuclear HIF1{alpha}/c-Jun interaction plays an important role in mediating the JNK pathway-induced increase of HIF1 binding to the HRE in the MDR1 promoter.

MDR1 Repression in Normoxia and Activation in Hypoxia by the JNK Pathway Are Mediated by HDAC5 and p300/CBP, Respectively—To gain more mechanistic insights into the PO2-dependent differential regulation of MDR1 expression by the JNK pathway, we sought to look for additional protein partners of the c-Jun transcription factor. In yeast two-hybrid experiments using c-Jun as bait, we identified several clones of different sizes that encode for HDAC5, a transcriptional repressor belonging to the class II HDAC family (19). Immunoprecipitation of the nuclear lysate with a c-Jun antibody revealed that in normoxia c-Jun interacted with HDAC5 in the nucleus (Fig. 4A). However, the interaction between nuclear HDAC5 and c-Jun was not detected under the hypoxic condition (Fig. 4A). A parallel immunoprecipitation experiment with a HIF1{alpha} antibody revealed an association of nuclear HIF1{alpha} with c-Jun, but not with HDAC5, in hypoxia (Fig. 4B).

HDAC5 is known to repress gene transcription by promoting histone deacetylation and generating a stabilized, transcriptionally repressive chromatin structure (20). The interaction between HDAC5 and c-Jun in normoxia suggests that the activity of HDAC5 might underlie the JNK pathway-induced repression of MDR1 under the normoxic condition. To test this possibility, we examined the effects of JNK and c-Jun on MDR1 promoter activity in the presence of a dominant-negative, catalytic mutant of HDAC5. As shown in Fig. 4C, the repression of MDR1 promoter activity by JNK and c-Jun in normoxia was largely blocked by dominant-negative HDAC5. In contrast, JNK or c-Jun-induced up-regulation of MDR1 in hypoxia was not obviously affected. These results thus reveal a role for HDAC5 in mediating the down-regulatory effect of the JNK pathway on MDR1 expression in normoxia.

We next investigated whether in hypoxia the HIF1{alpha}-dependent MDR1 activation by the JNK pathway requires the p300/CBP transcriptional coactivator, which is known to contain histone acetyltransferase activity and promote the transcriptional activity of HIF1{alpha} (21, 22). Consistent with previous findings, our data also revealed that p300/CBP interacted with HIF1{alpha} in the nucleus (data not shown). In addition, we found that the JNK pathway-induced MDR1 activation in hypoxia was significantly abrogated by co-transfection with the adenoviral oncoprotein E1A, a well known suppressor of p300/CBP activity (23); in contrast, a mutant E1A, which is unable to bind p300/CBP (23), did not inhibit JNK pathway-induced MDR1 activation (Fig. 4D). These results indicate that in hypoxia the HIF1{alpha}-dependent up-regulatory effect of the JNK pathway on MDR1 expression requires the activity of the p300/CBP coactivator.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Drug resistance, particularly multidrug resistance, is a primary cause of cancer chemotherapy failure. A major mechanism underlying MDR is excessive induction of the MDR1 gene, ultimately leading to enhanced expression of P-glycoprotein in the plasma membrane. P-glycoprotein extrudes a wide spectrum of chemotherapeutic agents out of cells, causing decreased intracellular drug accumulation and therefore decreased drug effectiveness. MDR1/P-glycoprotein overexpression has been reported to confer MDR in cultured cancer cells and has also been correlated with drug resistance and poor prognosis in cancer patients (24, 25). However, it remains largely unknown how MDR1 expression is up-regulated in various types of cancer. Elucidating the molecular events that regulate MDR1 expression may contribute to the development of appropriate agents combating MDR and improving chemotherapeutic efficacy.


Figure 4
View larger version (29K):
[in this window]
[in a new window]

  		FIGURE 4.
MDR1 repression in normoxia and activation in hypoxia by the JNK pathway are mediated by HDAC5 and p300/CBP, respectively. The values shown in the graphs represent means ± S.D. of data from three independent experiments. A, examination of nuclear HDAC5/c-Jun interaction in HOP62 cells in normoxia and hypoxia by immunoprecipitation (IP) of the nuclear lysate with a c-Jun antibody followed by Western blot analysis with antibodies against HDAC5 and c-Jun. A nonspecific antibody was used in the immunoprecipitation as a negative control for the c-Jun antibody. B, examination of nuclear HDAC5/HIF1{alpha} and c-Jun/HIF1{alpha} interactions in HOP62 cells in hypoxia, by immunoprecipitation of the nuclear lysate with a HIF1{alpha} antibody followed by Western blot analysis with antibodies against HDAC5, c-Jun, and HIF1{alpha}. A nonspecific antibody was used in the immunoprecipitation as a negative control for the HIF1{alpha} antibody. C, HOP62 cells were transfected for 24 h in normoxia or hypoxia with pMDR1-Luc, pRL-TK, and pCDNA3-JNK, pCDNA3-c-Jun, or the control plasmid pCDNA3, together with a plasmid expressing dominant-negative HDAC5 (pRK5-HDAC5-DN) or the control plasmid pRK5. MDR1 promoter activity was calculated by dividing the measured firefly luciferase activity with the measured Renilla luciferase activity. The unit shown in the y axis is relative, with MDR1 promoter activity in cells transfected with the control plasmids pCDNA3 and pRK5 in normoxia set at 1. D, HOP62 cells were transfected for 24 h in normoxia or hypoxia with pMDR1-Luc, pRL-TK, and pCDNA3-JNK, pCDNA3-c-Jun, or the control plasmid pCDNA3, together with a plasmid expressing E1A (pCDNA3.1-E1A), E1A mutant (pCDNA3.1-E1A{Delta} 4–25), or the control plasmid, pCDNA3.1. MDR1 promoter activity was calculated by dividing the measured firefly luciferase activity with the measured Renilla luciferase activity. The unit shown in the y axis is relative, with MDR1 promoter activity in cells transfected with the control plasmid pCDNA3.1 in normoxia set at 1.

 
Recent studies have demonstrated that oxygen deprivation within the microenvironment of developing tumors can induce MDR1 gene expression in a HIF1-dependent manner (3, 4), and JNK activation has been suggested to mediate the above effect (6–8). Intriguingly, in normoxia JNK activity appears to negatively correlate with MDR1 expression (9–11). Although it is still ambiguous today as to how JNK functions in MDR1 expression, our results demonstrate clearly that the JNK pathway down-regulates MDR1 expression in normoxia and up-regulates MDR1 expression in hypoxia. These data provide the first direct evidence that the JNK pathway plays different PO2-dependent roles in regulating MDR1 expression. In addition, these data suggest that strategies targeting the JNK pathway for the manipulation of MDR should include PO2 as a critical factor of consideration.

MDR1 expression is known to undergo transcriptional regulation (24, 26). The MDR1 promoter bears a number of binding sites for transcription factors such as Y-box-binding protein 1, nuclear transcription factor Y, and the Sp1 transcription factor (27–29), as well as AP1 (c-Jun/c-Fos, etc.) and HIF1 (3, 18). In addition, cross-coupled nuclear factor-{kappa}B/p65 and c-Fos transcription factors are shown to bind to the CAAT box in the MDR1 promoter, to negatively regulate MDR1 expression (30), and p53 is shown to regulate MDR1 either positively or negatively (31, 32). The data in the present study show that the JNK pathway-induced down-regulation of MDR1 in normoxia is mediated by increased c-Jun binding to the AP1 site in the MDR1 promoter, whereas the JNK pathway-induced up-regulation of MDR1 in hypoxia is mediated by increased HIF1 binding to the HRE in the MDR1 promoter. A natural question to be addressed in the future then is how c-Jun and HIF1 coordinate with other transcription factors in regulating MDR1 expression under both normoxic and hypoxic conditions. Our data reveal that in hypoxia, the JNK pathway-induced increase in HIF1 binding to the HRE in the MDR1 promoter is mediated by the interaction between nuclear HIF1{alpha} and c-Jun. It will be interesting to investigate, in the future, whether the HIF1{alpha}/c-Jun interaction is direct or is mediated by other protein(s) present in the nucleus. In this study, we have also presented evidence that MDR1 repression in normoxia and activation in hypoxia by the JNK pathway are mediated by the HDAC5 transcriptional repressor and the p300/CBP transcriptional coactivator, respectively. These data provide important mechanistic insights into the PO2-dependent differential regulation of MDR1 expression by the JNK pathway.


   FOOTNOTES
 
* This work was supported by grants from the Ministry of Science and Technology of China (2006CB910100), the Tianjin Natural Science Foundation (06YFJMJC07000), and the National Natural Science Foundation of China (30600313) (to J. Z.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. 1. Back

1 To whom correspondence should be addressed: Dept. of Genetics and Cell Biology, College of Life Sciences, Nankai University, 94 Weijin Rd., Tianjin 300071, China. Tel. and Fax: 86-22-2350-4946; E-mail: junzhou{at}nankai.edu.cn.

2 The abbreviations used are: HIF1, hypoxia-inducible factor 1; MDR, multidrug resistance; JNK, c-Jun NH2-terminal kinase; AP1, activator protein 1; HRE, hypoxia response element; HDAC, histone deacetylase; CREB, cAMP-response element-binding protein; CBP, CREB-binding protein; m.o.i., multiplicity of infection; MKK, mitogen-activated protein kinase kinase; MEKK, mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) kinase kinase; RT, reverse transcription; siRNA, small interfering RNA. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Harris, A. L. (2002) Nat. Rev. Cancer 2, 38–47[CrossRef][Medline] [Order article via Infotrieve]
  2. Semenza, G. L. (1999) Annu. Rev. Cell Dev. Biol. 15, 551–578[CrossRef][Medline] [Order article via Infotrieve]
  3. Comerford, K. M., Wallace, T. J., Karhausen, J., Louis, N. A., Montalto, M. C., and Colgan, S. P. (2002) Cancer Res. 62, 3387–3394[Abstract/Free Full Text]
  4. Wartenberg, M., Ling, F. C., Muschen, M., Klein, F., Acker, H., Gassmann, M., Petrat, K., Putz, V., Hescheler, J., and Sauer, H. (2003) FASEB J. 17, 503–505[Abstract/Free Full Text]
  5. Brown, J. M., and Giaccia, A. J. (1998) Cancer Res. 58, 1408–1416[Abstract/Free Full Text]
  6. Comerford, K. M., Cummins, E. P., and Taylor, C. T. (2004) Cancer Res. 64, 9057–9061[Abstract/Free Full Text]
  7. Osborn, M. T., and Chambers, T. C. (1996) J. Biol. Chem. 271, 30950–30955[Abstract/Free Full Text]
  8. Ledoux, S., Yang, R., Friedlander, G., and Laouari, D. (2003) Cancer Res. 63, 7284–7290[Abstract/Free Full Text]
  9. Kang, C. D., Ahn, B. K., Jeong, C. S., Kim, K. W., Lee, H. J., Yoo, S. D., Chung, B. S., and Kim, S. H. (2000) Exp. Cell Res. 256, 300–307[CrossRef][Medline] [Order article via Infotrieve]
  10. Miao, Z. H., and Ding, J. (2003) Cancer Res. 63, 4527–4532[Abstract/Free Full Text]
  11. Zhou, J., Liu, M., Aneja, R., Chandra, R., Lage, H., and Joshi, H. C. (2006) Cancer Res. 66, 445–452[Abstract/Free Full Text]
  12. Zhou, J., Gupta, K., Yao, J., Ye, K., Panda, D., Giannakakou, P., and Joshi, H. C. (2002) J. Biol. Chem. 277, 39777–39785[Abstract/Free Full Text]
  13. Liu, M., Aneja, R., Liu, C., Sun, L., Gao, J., Wang, H., Dong, J. T., Sarli, V., Giannis, A., Joshi, H. C., and Zhou, J. (2006) J. Biol. Chem. 281, 18090–18097[Abstract/Free Full Text]
  14. Chen, C., Sun, X., Guo, P., Dong, X. Y., Sethi, P., Cheng, X., Zhou, J., Ling, J., Simons, J. W., Lingrel, J. B., and Dong, J. T. (2005) J. Biol. Chem. 280, 41553–41561[Abstract/Free Full Text]
  15. Strauss, B. E., and Haas, M. (1995) Biochem. Biophys. Res. Commun. 217, 333–340[CrossRef][Medline] [Order article via Infotrieve]
  16. Davis, R. J. (2000) Cell 103, 239–252[CrossRef][Medline] [Order article via Infotrieve]
  17. Ueda, K., Pastan, I., and Gottesman, M. M. (1987) J. Biol. Chem. 262, 17432–17436[Abstract/Free Full Text]
  18. Ikeguchi, M., Teeter, L. D., Eckersberg, T., Ganapathi, R., and Kuo, M. T. (1991) DNA Cell Biol. 10, 639–649[Medline] [Order article via Infotrieve]
  19. Grozinger, C. M., Hassig, C. A., and Schreiber, S. L. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 4868–4873[Abstract/Free Full Text]
  20. Bertos, N. R., Wang, A. H., and Yang, X. J. (2001) Biochem. Cell Biol. 79, 243–252[CrossRef][Medline] [Order article via Infotrieve]
  21. Arany, Z., Huang, L. E., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M. A., Bunn, H. F., and Livingston, D. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 12969–12973[Abstract/Free Full Text]
  22. Ebert, B. L., and Bunn, H. F. (1998) Mol. Cell. Biol. 18, 4089–4096[Abstract/Free Full Text]
  23. Arany, Z., Newsome, D., Oldread, E., Livingston, D. M., and Eckner, R. (1995) Nature 374, 81–84[CrossRef][Medline] [Order article via Infotrieve]
  24. Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., and Gottesman, M. M. (1999) Annu. Rev. Pharmacol. Toxicol. 39, 361–398[CrossRef][Medline] [Order article via Infotrieve]
  25. Gottesman, M. M., Fojo, T., and Bates, S. E. (2002) Nat. Rev. Cancer 2, 48–58[CrossRef][Medline] [Order article via Infotrieve]
  26. Baker, E. K., and El-Osta, A. (2004) Cancer Biol. Ther. 3, 819–824[Medline] [Order article via Infotrieve]
  27. Cornwell, M. M., and Smith, D. E. (1993) J. Biol. Chem. 268, 19505–19511[Abstract/Free Full Text]
  28. Jin, S., and Scotto, K. W. (1998) Mol. Cell. Biol. 18, 4377–4384[Abstract/Free Full Text]
  29. Ohga, T., Uchiumi, T., Makino, Y., Koike, K., Wada, M., Kuwano, M., and Kohno, K. (1998) J. Biol. Chem. 273, 5997–6000[Abstract/Free Full Text]
  30. Ogretmen, B., and Safa, A. R. (1999) Biochemistry 38, 2189–2199[CrossRef][Medline] [Order article via Infotrieve]
  31. Lecureur, V., Thottassery, J. V., Sun, D., Schuetz, E. G., Lahti, J., Zambetti, G. P., and Schuetz, J. D. (2001) Oncogene 20, 303–313[CrossRef][Medline] [Order article via Infotrieve]
  32. Li, Z. H., Zhu, Y. J., and Lit, X. T. (1997) Cancer Lett. 119, 177–184[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/24/17581    most recent
M702206200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, M.
Right arrow Articles by Zhou, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, M.
Right arrow Articles by Zhou, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.